Immunome CSO sells 13.2K shares, exercises options
Immunome’s chief scientific officer exercised options, sold shares under a Rule 10b5-1 plan, and made a share gift while retaining a significant option position.
Rhea-AI Filing Summary
Immunome Inc. (IMNM) reported that Chief Scientific Officer Jack Higgins exercised options for 18,000 shares of common stock on September 11, 2026 at an exercise price of $1.35 per share, resulting in 133,840 options remaining outstanding under this grant. On the same date, he sold 13,200 shares of common stock at an average price of $25.32 per share pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2025, and made a bona fide gift of 8,800 shares. In addition, three custodial accounts for his children each hold 1,000 shares, for which he serves as custodian and disclaims beneficial ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
7 txns
Insider
Higgins Jack
Role
Chief Scientific Officer
Sold
13,200 shs ($334K)
Approx. gross sale proceeds
$334K
Approx. exercise cost
$24K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) F3 | 18,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 18,000 | $1.35 | $24K |
| Sale | Common Stock F1 | 13,200 | $25.32 | $334K |
| Gift | Common Stock | 8,800 | $0.00 | $0.00 |
| holding | Common Stock F2 | -- | -- | -- |
| holding | Common Stock F2 | -- | -- | -- |
| holding | Common Stock F2 | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 133,840 contracts (Direct);
Common Stock — 56,250 shares (Direct);
Common Stock — 1,000 shares (Indirect, As Custodian for Child 1);
Common Stock — 1,000 shares (Indirect, As Custodian for Child 2);
Common Stock — 1,000 shares (Indirect, As Custodian for Child 3)
Footnotes (3)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.
- F2. The Reporting Person serves as a custodian of a custodial account for his child pursuant to the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose.
- F3. 25% of the shares subject to the options vested on May 1, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to the options vests every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Key Figures
Options exercised: 18,000 shares
Option exercise price: $1.35 per share
Shares sold: 13,200 shares
+4 more
7 metrics
Options exercised
18,000 shares
Options for Immunome common stock exercised on September 11, 2026
Option exercise price
$1.35 per share
Exercise price for the 18,000 options converted into common stock
Shares sold
13,200 shares
Common stock sale on September 11, 2026
Sale price
$25.32 per share
Average price for the 13,200 Immunome shares sold
Shares gifted
8,800 shares
Bona fide gift of Immunome common stock on September 11, 2026
Options remaining
133,840 shares
Options remaining outstanding under the reported grant after the exercise
Custodial holdings per child
1,000 shares
Indirect holdings in each of three custodial accounts for his children
Key Terms
Rule 10b5-1 trading plan, Uniform Transfer to Minors Act, beneficial ownership, vesting
4 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Uniform Transfer to Minors Act regulatory
"custodial account for his child pursuant to the Uniform Transfer to Minors Act"
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of these shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
vesting financial
"25% of the shares subject to the options vested on May 1, 2023"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did IMNM’s Chief Scientific Officer report in this Form 4?
He exercised options for 18,000 shares of Immunome common stock at $1.35 per share, sold 13,200 shares at $25.32 per share under a Rule 10b5-1 plan, and made a gift of 8,800 shares on September 11, 2026.
At what prices did the IMNM transactions occur on September 11, 2026?
The options were exercised at $1.35 per share, resulting in common stock. The 13,200 shares sold of Immunome common stock were sold at an average price of $25.32 per share. The 8,800-share gift was reported at $0.00 per share, reflecting a bona fide gift.
How many Immunome options does the Chief Scientific Officer hold after these transactions?
After exercising 18,000 options, the report shows that options covering 133,840 shares of Immunome common stock remain outstanding under the reported option award, subject to its vesting schedule and expiration date of June 23, 2032.
Does the IMNM executive have any indirect holdings for family members?
Yes. Three custodial accounts for his children each hold 1,000 shares of Immunome common stock. He serves as custodian under the Uniform Transfer to Minors Act and disclaims beneficial ownership of these shares.
What is the vesting schedule of the exercised IMNM stock options?
The filing states that 25% of the option shares vested on May 1, 2023, and one-thirty-sixth of the remaining shares vests each month thereafter, subject to Jack Higgins’ continuous service through each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
